CD24-Targeted NIR-II Fluorescence Imaging Enables Early Detection of Colorectal Neoplasia
Colorectal cancer continues to be a major health issue even though screening methods have facilitated early detection. Despite the high sensitivity of white-light colonoscopy, it frequently overlooks invasive flat or depressed lesions, which can lead to the development of larger, advanced tumors. Fluorescence molecular imaging offers a promising approach for early tumor detection by targeting specific molecular characteristics of lesions. CD24 is upregulated during the adenoma-to-colorectal cancer transition, providing a potential target for fluorescence molecular imaging. In this study, we developed a second near-infrared window (NIR-II) fluorescent probe with a high affinity for CD24 and evaluated its efficacy and targeting ability in cellular models, murine models, and clinical samples of colorectal cancer. CD24 expression was elevated in 76% of adenomas and 80% of colorectal cancers. In a colitis-associated cancer mouse model, NIR-II imaging with the CD24-targeted probe achieved a significantly higher tumor-to-background ratio compared with conventional NIR-I imaging. The probe demonstrated exceptional sensitivity (92%) and specificity (92%) for detecting colorectal cancer, including small lesions less than 1 mm in size. This led to the identification of precancerous lesions missed by white-light detection and lesions missed by NIR-I imaging. Moreover, ex vivo human tissue incubation with the probe supported the potential for intraprocedural lesion identification via topical probe application during colonoscopy. In conclusion, this study successfully demonstrates the potential of CD24-targeted NIR-II imaging for identifying colorectal neoplasia, highlighting its significance for early colorectal cancer detection in the gastrointestinal tract. Significance: Overexpression of CD24 in colorectal dysplasia provides the opportunity to use an NIR-II fluorescent probe targeting CD24 to detect colorectal neoplasms, including invisible lesions that are missed by white-light colonoscopy.
Authors
- Miaomiao Li (ORCID: https://orcid.org/0000-0002-9987-380X)
- Haifeng Liu (ORCID: https://orcid.org/0000-0003-3243-5984)
- Xiaojing Shi (ORCID: https://orcid.org/0000-0001-6303-3676)
- Yuanhao Qu
- Zhenhua Hu (ORCID: https://orcid.org/0000-0002-4600-3405)
- Lidan Fu (ORCID: https://orcid.org/0000-0003-4605-4277)
- Xiangyu Gao (ORCID: https://orcid.org/0000-0002-1697-1157)
- Zeyu Zhang (ORCID: https://orcid.org/0000-0002-4035-4028)
- Jie Tian (ORCID: https://orcid.org/0000-0003-0498-0432)
- Caiguang Cao (ORCID: https://orcid.org/0000-0001-8518-7449)
- Shuangling Luo (ORCID: https://orcid.org/0000-0001-9732-894X)
- Xiaofeng Wang
- Xiaoyong Guo
- Yingying Cui
Institutions
- National Kidney Foundation (US)
- Xidian University (CN)
- Sun Yat-sen University (CN)
- Chinese Academy of Sciences (CN)
- Peking University (CN)
- Harbin Institute of Technology (CN)
- Mengo Hospital (UG)
- Chinese PLA General Hospital (CN)
- Sixth Affiliated Hospital of Sun Yat-sen University (CN)
- Peking University Cancer Hospital (CN)
- Shandong Institute of Automation (CN)
- Beijing Academy of Artificial Intelligence (CN)
- Institute of Automation (CN)
- First Affiliated Hospital of Chinese PLA General Hospital (CN)
- Ministry of Education (ET)
- Beijing Chuiyangliu Hospital (CN)
- University of Chinese Academy of Sciences (CN)
- Beihang University (CN)
- Ministry of Industry and Information Technology (CN)
Publication Details
- Journal
- Cancer Research
- Published
- 2024-09-17
- DOI
- https://doi.org/10.1158/0008-5472.can-24-0012
- Citations
- 7
- Primary Topic
- Nanoplatforms for cancer theranostics
- Type
- article
- Field-Weighted Citation Impact
- 1.29